VYNE (VYNE) CFO has 4,007 shares withheld to cover RSU taxes

Rhea-AI Filing Summary

VYNE Therapeutics Chief Financial Officer Zeronda Tyler reported an automatic tax-related share disposition. On the vesting of restricted stock units, 4,007 shares of common stock were withheld by the company at $0.5975 per share to cover tax obligations. After this non-market transaction, Tyler directly holds 99,788 shares of VYNE common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Zeronda Tyler

Role CHIEF FINANCIAL OFFICER

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	4,007	$0.5975	$2K

Holdings After Transaction: Common Stock — 99,788 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 4,007 shares Withholding price per share: $0.5975 per share Shares held after transaction: 99,788 shares

3 metrics

Shares withheld for taxes 4,007 shares Withheld to satisfy tax obligations on RSU vesting

Withholding price per share $0.5975 per share Valuation used for the 4,007 withheld shares

Shares held after transaction 99,788 shares CFO’s direct VYNE common stock holdings after withholding

Key Terms

restricted stock units, tax withholding requirements, Form 4

3 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding requirements financial

"withheld by the Issuer to satisfy tax withholding requirements"

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zeronda Tyler

(Last) (First) (Middle)

C/O VYNE THERAPEUTICS INC.

P.O. BOX 125

(Street)

STEWARTSVILLE NEW JERSEY 08886

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VYNE Therapeutics Inc. [ VYNE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		F(1)		4,007	D	$0.5975	99,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy tax withholding requirements in connection with the vesting of restricted stock units.

	/s/ Mutya Harsch, Attorney-in-Fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did VYNE (VYNE) CFO Zeronda Tyler report on this Form 4?

VYNE Therapeutics CFO Zeronda Tyler reported a tax-related share disposition. The company withheld 4,007 common shares upon restricted stock unit vesting to satisfy tax withholding obligations, a routine administrative event rather than an open-market stock sale.

How many VYNE (VYNE) shares were withheld for taxes from the CFO?

The company withheld 4,007 VYNE common shares to cover tax obligations. These shares were retained by the issuer when restricted stock units vested, rather than being sold into the market by the executive on an exchange.

At what price were the withheld VYNE (VYNE) shares valued?

The withheld 4,007 VYNE shares were valued at $0.5975 per share. This price is used in the filing to calculate the value of stock withheld to satisfy the CFO’s tax withholding requirement tied to restricted stock unit vesting.

How many VYNE (VYNE) shares does the CFO hold after this Form 4 event?

After the tax-withholding event, CFO Zeronda Tyler directly holds 99,788 VYNE common shares. This figure reflects her remaining position following the withholding of 4,007 shares by the company to meet associated tax obligations on vested restricted stock units.

Was this VYNE (VYNE) Form 4 an open-market sale by the CFO?

No, this Form 4 does not report an open-market sale. It records shares withheld by VYNE Therapeutics to satisfy tax withholding requirements when restricted stock units vested, a mechanical disposition rather than a discretionary stock sale by the CFO.